Abstract 1422P
Background
Advances in therapies for patients with NSCLC require personalizing treatment based on patients' tumor genetic profiles to improve outcomes. Approaches to evaluate tumor biomarkers include a range of testing from single gene/small panel to CGP which includes hundreds of genes and signatures like TMB and MSI. This study compared actionable biomarker detection, targeted therapy receipt, and clinical outcomes in patients with aNSCLC tested with CGP vs small panels (SP).
Methods
This is a retrospective study of adult patients in the US community setting diagnosed with aNSCLC between 1/1/2015 and 12/31/2020. Patients were followed from aNSCLC diagnosis (index) until the earliest of death or study-end and (9/30/2021) categorized based on the most comprehensive testing during follow-up as SP (≤52 genes) or CGP (>52 genes). Biomarker actionability was defined by OncoKB1: FDA recognized (Level 1), standard of care (Level 2), standard of care predictive of resistance (Level R1). Likelihood of receipt of matched therapy was assessed using logistic regression; Kaplan-Meier and Cox proportional hazards models were used to assess real- world overall survival (rwOS).
Results
Among 3,884 patients (median age 68y, 50% female, 73% Non-Hispanic White), 20% received CGP and 80% SP as the most comprehensive test. The proportion of patients with ≥1 actionable biomarker was significantly higher in CGP than SP (32% vs 14%; p<0.001). Of patients with actionable biomarkers, 43%(CGP) and 38% (SP) received matched therapies (p=0.20). Among treated patients: (1) CGP prior to 1st line treatment was associated with higher likelihood of receiving matched therapy (OR=3.21[95%CI: 1.98, 5.19]); (2) patients receiving CGP testing during follow-up had greater median rwOS (22 months[95%CI:18-25] vs. 15 months[95%CI:14-16]) and reduced risk of mortality (HR: 0.80[95% CI: 0.72, 0.89]) compared to SP.
Conclusions
Patients who received CGP had improved use of matched therapies and greater rwOS compared to SP. . Broader adoption of CGP may improve detection of actionable biomarkers, facilitating appropriate timely delivery of precision therapies resulting in better outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Syapse Inc.
Funding
Illumina, Inc.
Disclosure
G. Simon: Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, AstraZeneca, Dava Oncology, Merck, Reflexion, Genprex, Syapse , IDP Pharma, Onc. AI ; Financial Interests, Personal, Invited Speaker: Celegene, AstraZeneca, OncoLive, Nexus Oncology, PER Oncology; Financial Interests, Personal, Research Grant: Merck, BI. A. Berry: Financial Interests, Institutional, Stocks/Shares: Syapse; Financial Interests, Institutional, Full or part-time Employment: Syapse. B. Bapat: Financial Interests, Institutional, Stocks/Shares: Illumina. J. Law, C. Sweetnam, H. Mohammed, A. McBratney, M. Izano, M. Scannell Bryan: Financial Interests, Institutional, Full or part-time Employment: Syapse. S. Spencer, D. Hostin, B. Schroeder, P.G. Febbo: Financial Interests, Institutional, Full or part-time Employment: Illumina.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20